Can pre-treatment with beta-agonists reduce stress test time and the use of atropine in dobutamine stress testing?
Patients on short acting beta-agonists require smaller amounts of dobutamine with a shorter infusion time during DAS, and lesser use of side-effect prone atropine.
Lower degree of CA9 expression was associated with better clinical outcomes in patients with mCRC treated with lower dose bevacizumab-based chemotherapy. Prospective studies are now needed to determine the correlation between CA9 expression and clinical outcomes after bevacizumab treatment, at different doses and in varied settings.